DAVID CLEAVER
- Type
- Physician · Allopathic & Osteopathic Physicians / Dermatology
- Where
- KIRKSVILLE, MO
- NPI
- 1295932648
- Received
- $372,932 in 1,001 records, 2019 to 2025 ($371,481 general, $1,450 research)
- As principal investigator
- $417,276 of research payments to others in 161 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 186 | $59,540 |
| 2024 | General payment | 171 | $54,972 |
| 2023 | General payment | 187 | $80,047 |
| 2023 | Research payment | 7 | $1,450 |
| 2022 | General payment | 157 | $46,785 |
| 2021 | General payment | 105 | $40,497 |
| 2020 | General payment | 47 | $22,739 |
| 2019 | General payment | 141 | $66,899 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 87 | $287,757 |
| Travel and Lodging | 96 | $46,266 |
| Food and Beverage | 793 | $22,196 |
| Consulting Fee | 5 | $11,162 |
| Honoraria | 1 | $3,500 |
| Research payment | 7 | $1,450 |
| Education | 12 | $599 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-19 | Arcutis Biotherapeutics, Inc. | $12 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-12-17 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-12-16 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-12-10 | SUN PHARMACEUTICAL INDUSTRIES INC. | $22 | Food and Beverage | In-kind items and services | BLU-U Medical Supply, Dermatology | 2025 | |
| 2025-12-08 | ABBVIE INC. | $4,025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-12-08 | ABBVIE INC. | $4,025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-12-08 | ABBVIE INC. | $2,875 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-12-08 | UCB, Inc. | $17 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-12-01 | ABBVIE INC. | $2,875 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-11-26 | ABBVIE INC. | $4,025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-11-26 | Galderma Laboratories, L.P. | $11 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-11-25 | Ortho Dermatologics, a division of Bausch Health US, LLC | $19 | Food and Beverage | In-kind items and services | JUBLIA Drug, Podiatry | 2025 | |
| 2025-11-24 | Novartis Pharmaceuticals Corporation | $29 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-11-20 | Amgen Inc. | $12 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-11-19 | ABBVIE INC. | $12 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-11-19 | ABBVIE INC. | $9 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-11-18 | Arcutis Biotherapeutics, Inc. | $5 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-11-13 | ABBVIE INC. | $147 | Travel and Lodging | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-11-13 | ABBVIE INC. | $27 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-11-13 | ABBVIE INC. | $22 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-11-13 | ABBVIE INC. | $7 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-11-12 | Incyte Corporation | $18 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-11-11 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-11-10 | Arcutis Biotherapeutics, Inc. | $13 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-11-06 | ABBVIE INC. | $99 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-11-06 | ABBVIE INC. | $24 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-11-05 | Regeneron Healthcare Solutions, Inc. | $18 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-11-04 | Janssen Scientific Affairs, LLC | $109 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-11-03 | SUN PHARMACEUTICAL INDUSTRIES INC. | $20 | Food and Beverage | In-kind items and services | ILUMYA Biological, Dermatology | 2025 | |
| 2025-10-31 | ABBVIE INC. | $2,875 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-10-30 | Regeneron Healthcare Solutions, Inc. | $14 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-29 | ABBVIE INC. | $4,025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-10-28 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-10-22 | Amgen Inc. | $12 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-10-15 | Janssen Biotech, Inc. | $108 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-10-15 | Galderma Laboratories, L.P. | $10 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-10-13 | ABBVIE INC. | $1,474 | Travel and Lodging | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-10-13 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-10-13 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-10-11 | Arcutis Biotherapeutics, Inc. | $13 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-10-10 | Biofrontera Inc. | $24 | Education | In-kind items and services | AMELUZ Drug, DERMATOLOGY | 2025 | |
| 2025-10-09 | GENZYME CORPORATION | $16 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-10-09 | E.R. Squibb & Sons, L.L.C. | $2 | Food and Beverage | Cash or cash equivalent | Sotyktu Drug, Immunology | 2025 | |
| 2025-10-07 | Amgen Inc. | $15 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-10-03 | Regeneron Healthcare Solutions, Inc. | $9 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-30 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-09-30 | ABBVIE INC. | $7 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-09-24 | Organon Llc | $20 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-22 | Arcutis Biotherapeutics, Inc. | $13 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-09-20 | Regeneron Healthcare Solutions, Inc. | $73 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-19 | Lilly USA, LLC | $18 | Food and Beverage | In-kind items and services | TALTZ Drug, Immunology | 2025 | |
| 2025-09-17 | Novartis Pharmaceuticals Corporation | $23 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-09-17 | Novartis Pharmaceuticals Corporation | $2 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-09-15 | ABBVIE INC. | $23 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-12 | SUN PHARMACEUTICAL INDUSTRIES INC. | $21 | Food and Beverage | In-kind items and services | BLU-U Medical Supply, Dermatology | 2025 | |
| 2025-09-09 | PFIZER INC. | $14 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-09-04 | E.R. Squibb & Sons, L.L.C. | $1 | Food and Beverage | Cash or cash equivalent | Sotyktu Drug, Immunology | 2025 | |
| 2025-09-03 | Galderma Laboratories, L.P. | $5 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-08-28 | Amgen Inc. | $13 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-08-26 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-08-22 | Regeneron Healthcare Solutions, Inc. | $8 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-08-21 | SUN PHARMACEUTICAL INDUSTRIES INC. | $120 | Food and Beverage | In-kind items and services | DRIZALMA SPRINKLE Drug, Psychiatry Psychology | 2025 | |
| 2025-08-21 | Arcutis Biotherapeutics, Inc. | $13 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-08-19 | Amgen Inc. | $11 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-08-19 | Amgen Inc. | $2 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-08-18 | SUN PHARMACEUTICAL INDUSTRIES INC. | $23 | Food and Beverage | In-kind items and services | BLU-U Medical Supply, Dermatology | 2025 | |
| 2025-08-14 | Lilly USA, LLC | $13 | Food and Beverage | In-kind items and services | EBGLYSS Drug, Immunology | 2025 | |
| 2025-08-12 | E.R. Squibb & Sons, L.L.C. | $11 | Food and Beverage | Cash or cash equivalent | Sotyktu Drug, Immunology | 2025 | |
| 2025-08-11 | SUN PHARMACEUTICAL INDUSTRIES INC. | $18 | Food and Beverage | In-kind items and services | ILUMYA Biological, Dermatology | 2025 | |
| 2025-08-11 | Galderma Laboratories, L.P. | $10 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-08-07 | Novartis Pharmaceuticals Corporation | $18 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-08-06 | ABBVIE INC. | $4,025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-08-04 | Novartis Pharmaceuticals Corporation | $23 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-08-04 | Galderma Laboratories, L.P. | $3 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-07-31 | UCB, Inc. | $20 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-07-29 | Janssen Biotech, Inc. | $18 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-07-28 | PFIZER INC. | $15 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-07-28 | Amgen Inc. | $6 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-07-22 | Galderma Laboratories, L.P. | $2 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-07-21 | Novartis Pharmaceuticals Corporation | $9 | Food and Beverage | In-kind items and services | XOLAIR Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-07-21 | Galderma Laboratories, L.P. | $4 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-07-20 | Lilly USA, LLC | $21 | Food and Beverage | In-kind items and services | TALTZ Drug, Immunology | 2025 | |
| 2025-07-18 | ABBVIE INC. | $4,025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-07-18 | ABBVIE INC. | $1,182 | Travel and Lodging | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-07-18 | ABBVIE INC. | $1,141 | Travel and Lodging | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-07-18 | ABBVIE INC. | $56 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-07-15 | ABBVIE INC. | $125 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-06-30 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-06-26 | E.R. Squibb & Sons, L.L.C. | $14 | Food and Beverage | Cash or cash equivalent | Sotyktu Drug, Immunology | 2025 | |
| 2025-06-26 | Galderma Laboratories, L.P. | $2 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-06-25 | Galderma Laboratories, L.P. | $4 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-06-24 | PFIZER INC. | $19 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-06-23 | Amgen Inc. | $12 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-06-19 | Galderma Laboratories, L.P. | $116 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-06-16 | E.R. Squibb & Sons, L.L.C. | $11 | Food and Beverage | Cash or cash equivalent | Sotyktu Drug, Immunology | 2025 | |
| 2025-06-14 | Arcutis Biotherapeutics, Inc. | $12 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-06-06 | Novartis Pharmaceuticals Corporation | $13 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-06-04 | Galderma Laboratories, L.P. | $11 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-06-02 | Lilly USA, LLC | $16 | Food and Beverage | In-kind items and services | TALTZ Drug, Immunology | 2025 | |
| 2025-05-29 | UCB, Inc. | $16 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-05-20 | Arcutis Biotherapeutics, Inc. | $12 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-05-19 | GENZYME CORPORATION | $48 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-05-16 | Incyte Corporation | $135 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-05-16 | Regeneron Healthcare Solutions, Inc. | $23 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-05-16 | Novartis Pharmaceuticals Corporation | $9 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-05-15 | ABBVIE INC. | $2,300 | Consulting Fee | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-05-13 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-05-12 | E.R. Squibb & Sons, L.L.C. | $8 | Food and Beverage | Cash or cash equivalent | Sotyktu Drug, Immunology | 2025 | |
| 2025-05-12 | E.R. Squibb & Sons, L.L.C. | $1 | Food and Beverage | Cash or cash equivalent | Sotyktu Drug, Immunology | 2025 | |
| 2025-05-07 | ABBVIE INC. | $22 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-05-02 | Regeneron Healthcare Solutions, Inc. | $12 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-05-01 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-04-30 | SUN PHARMACEUTICAL INDUSTRIES INC. | $19 | Food and Beverage | In-kind items and services | BLU-U Medical Supply, Dermatology | 2025 | |
| 2025-04-29 | Galderma Laboratories, L.P. | $4 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-04-29 | Galderma Laboratories, L.P. | $3 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-04-28 | SUN PHARMACEUTICAL INDUSTRIES INC. | $24 | Food and Beverage | In-kind items and services | ILUMYA Biological, Dermatology | 2025 | |
| 2025-04-25 | Eli Lilly and Company | $99 | Education | In-kind items and services | 2025 | ||
| 2025-04-24 | Novartis Pharmaceuticals Corporation | $22 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-04-24 | E.R. Squibb & Sons, L.L.C. | $4 | Food and Beverage | Cash or cash equivalent | Sotyktu Drug, Immunology | 2025 | |
| 2025-04-23 | E.R. Squibb & Sons, L.L.C. | $59 | Food and Beverage | Cash or cash equivalent | Sotyktu Drug, Immunology | 2025 | |
| 2025-04-22 | Lilly USA, LLC | $18 | Food and Beverage | In-kind items and services | EBGLYSS Drug, Immunology | 2025 | |
| 2025-04-22 | Organogenesis Inc. | $17 | Food and Beverage | In-kind items and services | PURAPLY WOUND MATRIX Device, WOUND CARE | 2025 | |
| 2025-04-18 | Arcutis Biotherapeutics, Inc. | $16 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-04-16 | Galderma Laboratories, L.P. | $30 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-04-14 | E.R. Squibb & Sons, L.L.C. | $7 | Food and Beverage | Cash or cash equivalent | Sotyktu Drug, Immunology | 2025 | |
| 2025-04-10 | UCB, Inc. | $20 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-04-08 | UCB, Inc. | $10 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-04-04 | Lilly USA, LLC | $18 | Food and Beverage | In-kind items and services | TALTZ Drug, Immunology | 2025 | |
| 2025-04-03 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-04-02 | ABBVIE INC. | $9 | Education | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-04-02 | ABBVIE INC. | $1 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-04-01 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-03-31 | Janssen Biotech, Inc. | $18 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-03-30 | Galderma Laboratories, L.P. | $4 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-03-26 | SUN PHARMACEUTICAL INDUSTRIES INC. | $19 | Food and Beverage | In-kind items and services | ILUMYA Biological, Dermatology | 2025 | |
| 2025-03-25 | Galderma Laboratories, L.P. | $10 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-03-21 | Regeneron Healthcare Solutions, Inc. | $11 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-03-20 | Arcutis Biotherapeutics, Inc. | $9 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-03-18 | ABBVIE INC. | $4,025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-03-18 | ABBVIE INC. | $2,875 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-03-14 | ABBVIE INC. | $153 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-03-14 | ABBVIE INC. | $117 | Travel and Lodging | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-03-14 | ABBVIE INC. | $15 | Travel and Lodging | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-03-09 | Janssen Research & Development, LLC | $136 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-03-09 | LEO Pharma Inc. | $59 | Food and Beverage | In-kind items and services | ADBRY Biological, DERMATOLOGY | 2025 | |
| 2025-03-08 | Regeneron Healthcare Solutions, Inc. | $150 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-03-08 | Journey Medical Corporation | $97 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-03-07 | Amgen Inc. | $100 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-03-06 | E.R. Squibb & Sons, L.L.C. | $1,470 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Sotyktu Drug, Immunology | 2025 | |
| 2025-03-06 | Janssen Biotech, Inc. | $149 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-03-03 | UCB, Inc. | $19 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-02-27 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-02-25 | Organogenesis Inc. | $18 | Food and Beverage | In-kind items and services | CYGNUS DUAL Medical Supply, WOUND CARE | 2025 | |
| 2025-02-24 | ABBVIE INC. | $1,098 | Travel and Lodging | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-02-24 | ABBVIE INC. | $695 | Travel and Lodging | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-02-24 | ABBVIE INC. | $29 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-02-24 | ABBVIE INC. | $22 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-02-22 | SUN PHARMACEUTICAL INDUSTRIES INC. | $104 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-02-22 | E.R. Squibb & Sons, L.L.C. | $58 | Food and Beverage | Cash or cash equivalent | Sotyktu Drug, Immunology | 2025 | |
| 2025-02-21 | UCB, Inc. | $101 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-02-21 | ABBVIE INC. | $56 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-02-21 | E.R. Squibb & Sons, L.L.C. | $49 | Food and Beverage | Cash or cash equivalent | Sotyktu Drug, Immunology | 2025 | |
| 2025-02-21 | SUN PHARMACEUTICAL INDUSTRIES INC. | $34 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-02-20 | Regeneron Healthcare Solutions, Inc. | $71 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-02-20 | Novartis Pharmaceuticals Corporation | $35 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-02-18 | ABBVIE INC. | $4,025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-02-13 | UCB, Inc. | $17 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-02-12 | SUN PHARMACEUTICAL INDUSTRIES INC. | $16 | Food and Beverage | In-kind items and services | ILUMYA Biological, Dermatology | 2025 | |
| 2025-02-11 | E.R. Squibb & Sons, L.L.C. | $6 | Food and Beverage | Cash or cash equivalent | Sotyktu Drug, Immunology | 2025 | |
| 2025-02-11 | E.R. Squibb & Sons, L.L.C. | $0 | Food and Beverage | Cash or cash equivalent | Sotyktu Drug, Immunology | 2025 | |
| 2025-02-07 | Organon Llc | $5 | Food and Beverage | In-kind items and services | VTAMA Drug, Dermatology | 2025 | |
| 2025-02-05 | Novartis Pharmaceuticals Corporation | $20 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-02-05 | Novartis Pharmaceuticals Corporation | $0 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-02-04 | Janssen Biotech, Inc. | $22 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-02-03 | LEO Pharma Inc. | $15 | Food and Beverage | In-kind items and services | ADBRY Biological, DERMATOLOGY | 2025 | |
| 2025-01-28 | Amgen Inc. | $10 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-01-27 | Incyte Corporation | $18 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-01-27 | Arcutis Biotherapeutics, Inc. | $14 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-01-23 | Novartis Pharmaceuticals Corporation | $23 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-01-22 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-01-21 | ABBVIE INC. | $1,597 | Travel and Lodging | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-01-21 | ABBVIE INC. | $90 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-01-14 | Lilly USA, LLC | $15 | Food and Beverage | In-kind items and services | TALTZ Drug, Immunology | 2025 | |
| 2025-01-13 | E.R. Squibb & Sons, L.L.C. | $17 | Food and Beverage | Cash or cash equivalent | Sotyktu Drug, Immunology | 2025 | |
| 2025-01-09 | ABBVIE INC. | $22 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-01-08 | Regeneron Healthcare Solutions, Inc. | $22 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2024-12-19 | Arcutis Biotherapeutics, Inc. | $13 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2024 | |
| 2024-12-18 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2024 | |
| 2024-12-18 | ABBVIE INC. | $0 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2024 | |
| 2024-12-12 | Janssen Scientific Affairs, LLC | $119 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2024 | |
| 2024-12-12 | Regeneron Healthcare Solutions, Inc. | $17 | Food and Beverage | In-kind items and services | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | 2024 | |
| 2024-12-11 | PFIZER INC. | $20 | Food and Beverage | In-kind items and services | EUCRISA Drug, DERMATOLOGY | 2024 | |
| 2024-12-10 | GENZYME CORPORATION | $21 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2024 | |
| 2024-12-05 | ABBVIE INC. | $1,725 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | 2024 | |
| 2024-12-05 | Amgen Inc. | $25 | Food and Beverage | In-kind items and services | Otezla Drug, Inflammation | 2024 | |
| 2024-12-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | $26 | Food and Beverage | In-kind items and services | SPEVIGO Drug, IMMUNOLOGY | 2024 | |
| 2024-12-02 | Novartis Pharmaceuticals Corporation | $29 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2024 | |
| 2024-11-23 | Regeneron Healthcare Solutions, Inc. | $97 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-11-21 | Arcutis Biotherapeutics, Inc. | $12 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2024 | |
| 2024-11-20 | E.R. Squibb & Sons, L.L.C. | $20 | Food and Beverage | Cash or cash equivalent | Sotyktu Drug, Immunology | 2024 |
The latest 200 records of 1,001.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-25 | Janssen Research & Development, LLC | CLEAVER DERMATOLOGY | $4,230 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study t | 2025 |
| 2025-12-15 | Janssen Research & Development, LLC | CLEAVER DERMATOLOGY | $1,345 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Stu | 2025 |
| 2025-12-12 | Janssen Research & Development, LLC | CLEAVER DERMATOLOGY | $120 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study t | 2025 |
| 2025-12-01 | Janssen Research & Development, LLC | CLEAVER DERMATOLOGY | $1,745 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study t | 2025 |
| 2025-11-05 | ABBVIE INC. | CLEAVER DERMATOLOGY PC | $150 | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participant | 2025 |
| 2025-10-24 | Janssen Research & Development, LLC | CLEAVER DERMATOLOGY | $2,855 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study t | 2025 |
| 2025-10-23 | Janssen Research & Development, LLC | CLEAVER DERMATOLOGY | $243 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study t | 2025 |
| 2025-10-10 | Janssen Research & Development, LLC | CLEAVER DERMATOLOGY | $18,160 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study t | 2025 |
| 2025-09-22 | Janssen Research & Development, LLC | CLEAVER DERMATOLOGY | $4,266 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Stu | 2025 |
| 2025-09-08 | Janssen Research & Development, LLC | CLEAVER DERMATOLOGY | $3,490 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study t | 2025 |
| 2025-09-01 | Janssen Research & Development, LLC | CLEAVER DERMATOLOGY | $2,133 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Stu | 2025 |
| 2025-08-22 | Regeneron Pharmaceuticals, Inc. | CLEAVER DERMATOLOGY | $398 | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2025 |
| 2025-08-22 | Regeneron Pharmaceuticals, Inc. | CLEAVER DERMATOLOGY | $398 | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2025 |
| 2025-08-06 | ABBVIE INC. | CLEAVER DERMATOLOGY PC | $8,133 | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participant | 2025 |
| 2025-07-28 | Janssen Research & Development, LLC | CLEAVER DERMATOLOGY | $2,511 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study t | 2025 |
| 2025-07-18 | Regeneron Pharmaceuticals, Inc. | CLEAVER DERMATOLOGY | $398 | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2025 |
| 2025-07-18 | Regeneron Pharmaceuticals, Inc. | CLEAVER DERMATOLOGY | $398 | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2025 |
| 2025-06-30 | Janssen Research & Development, LLC | CLEAVER DERMATOLOGY | $4,932 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Stu | 2025 |
| 2025-06-25 | Eli Lilly and Company | CLEAVER DERMATOLOGY, P.C. | $9,382 | OBSERVATION PRIORITY E SHORT - LEBRIKIZUMAB - ATOPIC DERMATITIS | 2025 |
| 2025-06-23 | Janssen Research & Development, LLC | CLEAVER DERMATOLOGY | $7,211 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study t | 2025 |
| 2025-05-26 | Janssen Research & Development, LLC | CLEAVER DERMATOLOGY | $5,474 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Stu | 2025 |
| 2025-05-21 | Regeneron Pharmaceuticals, Inc. | CLEAVER DERMATOLOGY | $398 | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2025 |
| 2025-05-21 | Regeneron Pharmaceuticals, Inc. | CLEAVER DERMATOLOGY | $398 | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2025 |
| 2025-04-28 | Janssen Research & Development, LLC | CLEAVER DERMATOLOGY | $3,242 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Stu | 2025 |
| 2025-03-24 | Janssen Research & Development, LLC | CLEAVER DERMATOLOGY | $4,498 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Stu | 2025 |
| 2025-03-03 | Janssen Research & Development, LLC | CLEAVER DERMATOLOGY | $5,455 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Stu | 2025 |
| 2025-02-21 | Janssen Research & Development, LLC | CLEAVER DERMATOLOGY | $1,624 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Stu | 2025 |
| 2025-01-27 | Janssen Research & Development, LLC | CLEAVER DERMATOLOGY | $5,417 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Stu | 2025 |
| 2024-12-18 | ABBVIE INC. | CLEAVER DERMATOLOGY PC | $10,329 | A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab | 2024 |
| 2024-12-18 | Regeneron Pharmaceuticals, Inc. | CLEAVER DERMATOLOGY | $398 | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2024 |
| 2024-12-16 | Janssen Research & Development, LLC | CLEAVER DERMATOLOGY | $13,144 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Stu | 2024 |
| 2024-10-28 | Janssen Research & Development, LLC | CLEAVER DERMATOLOGY | $7,609 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Stu | 2024 |
| 2024-09-30 | Janssen Research & Development, LLC | CLEAVER DERMATOLOGY | $10,329 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Stu | 2024 |
| 2024-08-26 | Janssen Research & Development, LLC | CLEAVER DERMATOLOGY | $13,136 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Stu | 2024 |
| 2024-08-20 | Regeneron Pharmaceuticals, Inc. | CLEAVER DERMATOLOGY | $398 | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2024 |
| 2024-08-19 | Janssen Research & Development, LLC | CLEAVER DERMATOLOGY | $25,187 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Stu | 2024 |
| 2024-07-26 | Janssen Research & Development, LLC | CLEAVER DERMATOLOGY | $11,579 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Stu | 2024 |
| 2024-07-05 | ABBVIE INC. | CLEAVER DERMATOLOGY PC | $526 | A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab | 2024 |
| 2024-06-27 | Janssen Research & Development, LLC | CLEAVER DERMATOLOGY | $5,810 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Stu | 2024 |
| 2024-06-05 | ABBVIE INC. | CLEAVER DERMATOLOGY PC | $1,295 | Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) | 2024 |
| 2024-05-27 | Janssen Research & Development, LLC | CLEAVER DERMATOLOGY | $5,837 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Stu | 2024 |
| 2024-05-20 | Regeneron Pharmaceuticals, Inc. | CLEAVER DERMATOLOGY | $398 | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2024 |
| 2024-05-08 | ABBVIE INC. | CLEAVER DERMATOLOGY PC | $261 | Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) | 2024 |
| 2024-04-04 | ABBVIE INC. | CLEAVER DERMATOLOGY PC | $4,097 | A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab | 2024 |
| 2024-04-04 | ABBVIE INC. | CLEAVER DERMATOLOGY PC | $5,000 | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With M | 2024 |
| 2024-03-28 | Acrotech Biopharma Inc. | CLEAVER DERMATOLOGY | $3,363 | 246-13651-302 | 2024 |
| 2024-03-07 | ABBVIE INC. | CLEAVER DERMATOLOGY PC | $2,922 | A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab | 2024 |
| 2024-02-01 | ABBVIE INC. | CLEAVER DERMATOLOGY PC | $1,282 | A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab | 2024 |
| 2024-01-10 | ABBVIE INC. | CLEAVER DERMATOLOGY PC | $1,327 | Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) | 2024 |
| 2024-01-04 | ABBVIE INC. | CLEAVER DERMATOLOGY PC | $1,282 | A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab | 2024 |
| 2023-12-31 | ABBVIE INC. | CLEAVER DERMATOLOGY | $100 | A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab | 2023 |
| 2023-12-19 | Regeneron Pharmaceuticals, Inc. | CLEAVER DERMATOLOGY | $398 | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2023 |
| 2023-12-19 | Regeneron Pharmaceuticals, Inc. | CLEAVER DERMATOLOGY | $398 | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2023 |
| 2023-12-04 | ABBVIE INC. | CLEAVER DERMATOLOGY PC | $2,564 | A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab | 2023 |
| 2023-11-30 | Acrotech Biopharma Inc. | CLEAVER DERMATOLOGY | $1,935 | 246-13651-302 | 2023 |
| 2023-11-21 | Regeneron Pharmaceuticals, Inc. | CLEAVER DERMATOLOGY | $398 | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2023 |
| 2023-11-21 | Regeneron Pharmaceuticals, Inc. | CLEAVER DERMATOLOGY | $398 | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2023 |
| 2023-11-21 | Regeneron Pharmaceuticals, Inc. | CLEAVER DERMATOLOGY | $398 | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2023 |
| 2023-11-21 | Regeneron Pharmaceuticals, Inc. | CLEAVER DERMATOLOGY | $398 | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2023 |
| 2023-11-09 | Acrotech Biopharma Inc. | CLEAVER DERMATOLOGY | $987 | 246-13651-302 | 2023 |
| 2023-11-08 | ABBVIE INC. | CLEAVER DERMATOLOGY PC | $5,683 | A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab | 2023 |
| 2023-10-12 | ABBVIE INC. | CLEAVER DERMATOLOGY PC | $261 | Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) | 2023 |
| 2023-07-11 | ABBVIE INC. | CLEAVER DERMATOLOGY PC | $1,295 | Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) | 2023 |
| 2023-05-22 | Regeneron Pharmaceuticals, Inc. | CLEAVER DERMATOLOGY | $398 | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2023 |
| 2023-05-11 | ABBVIE INC. | CLEAVER DERMATOLOGY PC | $2,084 | Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) | 2023 |
| 2023-04-04 | ABBVIE INC. | CLEAVER DERMATOLOGY PC | $1,327 | Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) | 2023 |
| 2023-03-09 | ABBVIE INC. | CLEAVER DERMATOLOGY PC | $8,323 | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participant | 2023 |
| 2023-01-12 | ABBVIE INC. | CLEAVER DERMATOLOGY PC | $1,509 | Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) | 2023 |
| 2023-01-05 | Regeneron Pharmaceuticals, Inc. | CLEAVER DERMATOLOGY | $93 | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2023 |
| 2022-12-21 | Regeneron Pharmaceuticals, Inc. | CLEAVER DERMATOLOGY | $305 | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2022 |
| 2022-12-01 | Regeneron Pharmaceuticals, Inc. | CLEAVER DERMATOLOGY | $305 | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2022 |
| 2022-11-09 | ABBVIE INC. | CLEAVER DERMATOLOGY PC | $261 | Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) | 2022 |
| 2022-09-20 | Regeneron Pharmaceuticals, Inc. | CLEAVER DERMATOLOGY | $305 | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2022 |
| 2022-09-07 | ABBVIE INC. | CLEAVER DERMATOLOGY PC | $1,265 | Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) | 2022 |
| 2022-08-11 | ABBVIE INC. | CLEAVER DERMATOLOGY PC | $2,163 | Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) | 2022 |
| 2022-07-25 | Regeneron Pharmaceuticals, Inc. | CLEAVER DERMATOLOGY | $305 | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2022 |
| 2022-06-24 | Regeneron Pharmaceuticals, Inc. | CLEAVER DERMATOLOGY | $305 | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2022 |
| 2022-06-14 | ABBVIE INC. | CLEAVER DERMATOLOGY PC | $1,746 | Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) | 2022 |
| 2022-06-01 | Regeneron Pharmaceuticals, Inc. | CLEAVER DERMATOLOGY | $305 | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2022 |
| 2022-06-01 | Regeneron Pharmaceuticals, Inc. | CLEAVER DERMATOLOGY | $305 | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2022 |
| 2022-05-12 | ABBVIE INC. | CLEAVER DERMATOLOGY | $1,712 | A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal | 2022 |
| 2022-05-12 | ABBVIE INC. | CLEAVER DERMATOLOGY PC | $1,714 | Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) | 2022 |
| 2022-03-09 | ABBVIE INC. | CLEAVER DERMATOLOGY PC | $1,172 | Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) | 2022 |
| 2022-02-18 | Regeneron Pharmaceuticals, Inc. | CLEAVER DERMATOLOGY | $305 | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2022 |
| 2022-02-08 | Regeneron Pharmaceuticals, Inc. | CLEAVER DERMATOLOGY | $305 | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2022 |
| 2022-02-08 | Regeneron Pharmaceuticals, Inc. | CLEAVER DERMATOLOGY | $305 | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2022 |
| 2022-02-03 | ABBVIE INC. | CLEAVER DERMATOLOGY PC | $1,172 | Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) (Measure | 2022 |
| 2022-01-04 | Regeneron Pharmaceuticals, Inc. | CLEAVER DERMATOLOGY | $467 | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2022 |
| 2021-12-27 | Regeneron Pharmaceuticals, Inc. | CLEAVER DERMATOLOGY | $305 | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2021 |
| 2021-12-17 | Regeneron Pharmaceuticals, Inc. | CLEAVER DERMATOLOGY | $467 | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2021 |
| 2021-12-17 | Regeneron Pharmaceuticals, Inc. | CLEAVER DERMATOLOGY | $305 | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2021 |
| 2021-12-16 | Regeneron Pharmaceuticals, Inc. | CLEAVER DERMATOLOGY | $467 | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2021 |
| 2021-12-16 | Regeneron Pharmaceuticals, Inc. | CLEAVER DERMATOLOGY | $305 | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2021 |
| 2021-12-13 | Regeneron Pharmaceuticals, Inc. | CLEAVER DERMATOLOGY | $305 | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2021 |
| 2021-12-02 | ABBVIE INC. | CLEAVER DERMATOLOGY PC | $3,460 | A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects w | 2021 |
| 2021-09-13 | Regeneron Pharmaceuticals, Inc. | CLEAVER DERMATOLOGY | $467 | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2021 |
| 2021-09-07 | ABBVIE INC. | CLEAVER DERMATOLOGY PC | $1,172 | A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects w | 2021 |
| 2021-07-29 | ABBVIE INC. | CLEAVER DERMATOLOGY PC | $1,172 | A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects w | 2021 |
| 2021-07-12 | Regeneron Pharmaceuticals, Inc. | CLEAVER DERMATOLOGY | $467 | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2021 |
| 2021-05-27 | ABBVIE INC. | CLEAVER DERMATOLOGY PC | $3,428 | A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects w | 2021 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Kirksville, MO, county Adair County, MO, state Missouri; placed by its city name.
| Measure | Place (city or town) Kirksville, MO | County Adair County, MO | State Missouri |
|---|---|---|---|
| Population B01003 | 17,563 | 25,301 | 6,191,814 |
| Population, 2020 census P1 | 17,530 | 25,314 | 6,154,913 |
| Median age B01002 | 24.8 | 30.2 | 39.0 |
| Under 18 B01001 | 18.5% | 18.7% | 22.3% |
| 65 and over B01001 | 12.9% | 15.4% | 17.9% |
| Households B11001 | 6,251 | 9,126 | 2,508,227 |
| Foreign born B05002 | 7.5% | 5.4% | 4.5% |
| Median household income B19013 | $50,071 | $61,536 | $70,702 |
| Median family income B19113 | $72,338 | $79,677 | $91,360 |
| Per capita income B19301 | $32,582 | $34,223 | $39,695 |
| Poverty rate B17001 | 28.2% | 22.0% | 12.6% |
| Unemployment rate B23025 | 4.0% | 4.1% | 4.0% |
| Civilian labor force B23025 | 7,448 | 11,421 | 3,120,639 |
| Mean commute (minutes) B08013 | 12.7 | 15.3 | 23.5 |
| Bachelor's degree or higher B15003 | 40.3% | 35.5% | 32.4% |
| Housing units B25001 | 7,609 | 11,389 | 2,825,287 |
| Owner-occupied B25003 | 48.3% | 61.0% | 68.1% |
| Renters B25003 | 51.7% | 39.0% | 31.9% |
| Median home value B25077 | $153,900 | $165,700 | $230,300 |
| Median gross rent B25064 | $775 | $772 | $1,033 |
| White, not Hispanic B03002 | 82.9% | 87.1% | 76.3% |
| Black B03002 | 6.4% | 4.4% | 10.9% |
| Hispanic or Latino B03002 | 3.7% | 3.0% | 5.2% |
| Asian B03002 | 2.9% | 2.1% | 2.1% |
| American Indian and Alaska Native B03002 | 0.4% | 0.3% | 0.2% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Kirksville, MO.
Comments